Monthly Archives: May 2020

TMR estimates that the healthcare cleanroom consumables market features fragmented and highly competitive vendor landscape. The large number of companies present in the market is leading to increase level of competition in the global market. Some of the key players dominating the globalhealthcare cleanroom consumables marketare Valutek, Texwipe, Nitritex Ltd., DuPont, and Kimberly-Clark Corp. These key players collectively accounted for 52% of the overall revenue. Additionally, the key players are getting benefit from commercialization of products coupled with implication of cost-cutting measures during manufacturing. However, lack of product differentiation is creating challenge for key players. Thus, the players are increasingly trying to offer products at competitive pricing, and in turn, the intense price war is taking shape on a global level.

The analysts at TMR estimates, the global healthcare cleanroom consumables market is likely to exhibit growth at a CAGR of 4.76% during the period from 2015 to 2023. At this growth rate, the market is likely to reach a valuation of US$3 bn by 2023 from rising from a valuation of US$2 bn in 2014. This growth is attributable to rising need for new and effective drugs.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8227

On the basis of applications, the market is dominated by the segment of biotechnology and is estimated to remain dominant in the coming years. On the basis of geography, the market in North America is estimated to be the leading region in terms of revenue and to be dominant in coming years. The regional market stood at the US$0.7 bn in 2014 and is expected to grab a value of US$10.3 bn by the end of 2023. The Europe is expected to account for second-leading share and is estimated to grab a value of US$0.9 bn by 2023 from a value of US$0.6 bn in 2014. This growth is attributable to high demand for cleanroom consumables in the region coupled with increasing demand from the pharmaceuticals and biotechnology industry.

Booming Research Activities in Healthcare Drives Market Growth

The healthcare cleanroom consumable market has gained pace from past few years as the external factors such as chemicals, vapors, dust and other microorganisms in air is lowering the production capacity. Additionally, these external factors influence negatively on the products and facilities of drugs and medical devices. Thus, demand for the cleanroom consumables especially in the healthcare is growing substantially, which in turn is propelling growth of the healthcare cleanroom consumable market.

Request for Analysis of the COVID19 Impact on Healthcare Cleanroom Consumables Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=8227

Cleanroom consumables have robust applications in the healthcare and medical industry as the importance of cleanliness is higher in the sector, which is benefiting growth of the global healthcare cleanroom consumable market. The other sectors of the healthcare industry such as pharmaceuticals, devices, and hospitals are driving growth of the global healthcare cleanroom consumable market. Additionally, high demand for the cleanroom consumables from biotechnological labs is high as the devices can easily get affected due to organisms in the room or air. This is key factors driving growth of the healthcare cleanroom consumable market and is expected to be major factors influencing growth in coming years.

Need of High Investment Restrains Market Growth

However, requirement of high investment on healthcare cleanroom consumables and devices is restraining growth of the healthcare cleanroom consumable market. Additionally, availability of customized healthcare cleanroom consumables as per requirement is difficult which is hampering growth to some extent. Further, the healthcare cleanroom consumables such as gloves are not the reusable and require long time for recycling, which creates the challenge for key players. This is another key concerns and major factor slowing the growth of the healthcare cleanroom consumable market. Nonetheless, the continuous research and development coupled with robust investment and commercialization of biotechnological products for development of chronic diseases such as cancer is estimated to offer lucrative opportunities for growth in the healthcare cleanroom consumable market in coming years.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=8227

This information is encompassed inthe report by TMR, titled, Healthcare Cleanroom Consumables Market (Product - Wipers (Dry and Wet), Cleanroom Apparels(Coverall, Frock, Boot Cover, Shoe Cover, Bouffant, Sleeves, Pants, Face Masks, and Hood), Cleaning Products (Cleanroom Mops, Buckets, Wringers, Squeegees, Validation Swabs, and Cleaning Chemicals), and Cleanroom Stationery (Paper, Notebook and Adhesive Pads, Binders and Clipboards, and Labels); Application - Pharmaceutical, Biotechnology, Medical Devices, Academia, and Hospitals) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 20152023.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email:sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com

More:
Healthcare Cleanroom Consumables Market: Increasing Commercialization of Biotechnology-based Products to Boost the Demand - BioSpace

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) shareholders will doubtless be very grateful to see the share price up 54% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the share price is down 46% in the last three years, falling well short of the market return.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

B.R.A.I.N. Biotechnology Research and Information Network isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years, B.R.A.I.N. Biotechnology Research and Information Network saw its revenue grow by 19% per year, compound. That's a fairly respectable growth rate. Shareholders have endured a share price decline of 19% per year. This implies the market had higher expectations of B.R.A.I.N. Biotechnology Research and Information Network. However, that's in the past now, and it's the future is more important - and the future looks brighter (based on revenue, anyway).

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

XTRA:BNN Income Statement May 4th 2020

If you are thinking of buying or selling B.R.A.I.N. Biotechnology Research and Information Network stock, you should check out this FREE detailed report on its balance sheet.

B.R.A.I.N. Biotechnology Research and Information Network shareholders may not have made money over the last year, but their total loss of 6.2% isn't as bad as the market loss of around 6.2%. Furthermore, the stock lost shareholders 19% per year over three years, so the one-year return was better in a relative sense. It is of course not much comfort to know that the losses have slowed. Shareholders will be hoping for a proper turnaround, no doubt. It's always interesting to track share price performance over the longer term. But to understand B.R.A.I.N. Biotechnology Research and Information Network better, we need to consider many other factors. Take risks, for example - B.R.A.I.N. Biotechnology Research and Information Network has 1 warning sign we think you should be aware of.

Of course B.R.A.I.N. Biotechnology Research and Information Network may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DE exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View original post here:
The B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Share Price Is Down 46% So Some Shareholders Are Getting Worried - Yahoo...

Coronavirus Real-Time Detection Kits Market 2020

This report studies the Coronavirus Real-Time Detection Kits Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Coronavirus Real-Time Detection Kits Market analysis segmented by companies, region, type and applications in the report.

The major players covered in Coronavirus Real-Time Detection Kits Market Zhijiang biology, Sansure, Shanghai Huirui Biotechnology, Geneodx, Shanghai BioGerm Medical Biotechnology, Da An Gene, Wondfo, and INNOVITA

The final report will add the analysis of the Impact of Covid-19 in this report Coronavirus Real-Time Detection Kits industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-coronavirus-real-time-detection-kits-market-research-report-2020?utm_source=coleofduty&utm_medium=36

Coronavirus Real-Time Detection Kits Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Coronavirus Real-Time Detection Kits Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Coronavirus Real-Time Detection Kits market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Coronavirus Real-Time Detection Kits market by identifying its various sub segments.

Focuses on the key global Coronavirus Real-Time Detection Kits players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Coronavirus Real-Time Detection Kits with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Coronavirus Real-Time Detection Kits submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Coronavirus Real-Time Detection Kits Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents: Coronavirus Real-Time Detection Kits Market

Chapter 1: Overview of Coronavirus Real-Time Detection Kits Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Inquire More about This Report https://www.reportsandmarkets.com/enquiry/global-coronavirus-real-time-detection-kits-market-research-report-2020?utm_source=coleofduty&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original here:
Coronavirus Real-Time Detection Kits Market to Witness Astonishing Growth With Zhijiang biology, Sansure, Shanghai Huirui Biotechnology, Geneodx,...

FLORHAM PARK, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that the Company will release financial results for the first quarter ended March 31, 2020 on Wednesday, May 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, will host a conference call to review the financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am ET on Wednesday, May 13, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13703263.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Tram Bui / Alexander LoboThe Ruth GroupPhone: +1 (646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com / alobo@theruthgroup.com

The rest is here:
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results - GlobeNewswire

PRESS RELEASE

Algenex advances insect-based vaccine production technology in human health

Madrid, May 5, 2020.- Algenex SL (or the Company), a private biotechnology company delivering disruptive technologies for recombinant biologics production, announces that it is advancing the application of its CrisBio-based vaccine production technology in human health.

Building on its expertise in the production of proteins for veterinary vaccines, Algenex has started to produce biotechnology products for the development of human vaccines and other applications using CrisBio, its proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. CrisBio is a versatile and robust alternative to current bioreactor-based expression technologies and offers additional benefits including linear scalability, reduced production costs and increased productivity, reaching gram per litre yields.

Algenex has deep expertise in the production of proteins for the production of vaccines for zoonotic diseases that can be transferred to humans. The Company has completed a proof of concept study in avian influenza, a zoonotic disease with potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months, using animal models, an experience upon which it now intends to build to join the fight against pandemics.

According to Animal Health Europe, more than 2.2 million people die every year from zoonosis, with 75% of new infectious diseases affecting humans coming from animals, such as the recent COVID-19 pandemic.

Algenex CrisBio technology is able to produce proteins for vaccines more efficiently, economically and rapidly than current available bioreactor-based expression technologies, said Dr. Jos Escribano, founder and CSO of Algenex. As a result, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.

By expanding the use of our CrisBio technology into human health, we are now able to fully exploit the potential of this platform, said Claudia Jimnez, General Manager of Algenex. With CrisBio we are able to produce a new vector for the development of a potential new vaccine in less than two months. The insects we use as bioreactors are easy to rear in almost unlimited quantities and in a short period of time, allowing almost immediate and unlimited scalability once the parameters for the production have been defined.

For further information, please contact:

AlgenexClaudia JimnezGeneral ManagerT: +34 91 452 4941cjimenez@algenex.com

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex first two platforms, TopBac and CrisBio, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit http://www.algenex.com

[u

Continue reading here:
Algenex advances insect-based vaccine production technology in human health - GlobeNewswire

International Biotechnology Trust (IBT) invests primarily in US-based drug-makers with a global reach that meet a medical need for consumers. IBT is also the only biotech trust which caters to income-seeking investors, offering an attractive dividend of 4% of NAV as well as the potential for rapid capital growth.

Led by Carl Harald Janson, a medical doctor by background, IBTs investment team seeks out those businesses which can produce strong top-line growth. For this they need intellectual property which gives them pricing power and a competitive edge or monopoly. More than half the portfolio is invested in companies working in the specialisms of oncology (the treatment of cancer) and rare diseases, where barriers to entry are high. For example, one of the largest positions in the fund is in Vertex. A growth story in the treatment of rare diseases, it dominates the cystic fibrosis space, treating around 90% of patients.

At the geographical level, the fund is heavily skewed towards the US, the home of the biotech industry. It is well diversified across the market-cap spectrum, and holds, directly and indirectly, approximately 100 companies at different stages of development working in a range of therapeutic areas. The portfolio is predominantly in large and mid-caps, although it also holds some small-cap companies of less than $1bn in size.

Alongside the names in its listed company portfolio, IBT also has a smaller portfolio of unquoted biotech stocks, most of which are held through an investment in a venture fund, SV Fund VI. This unquoted portfolio has proven itself to be an excellent diversifier, making a significant contribution to performance last year when biotech stocks as a whole struggled.

Roughly two-thirds of the development of new drugs happens within smaller companies, while two-thirds of their commercialisation happens in large companies. This explains why merger and acquisition activity is so frequent within the biotech space. For IBT, this has been a happy side effect of choosing the strongest companies with the best valuations: 16 of the portfolios holdings have been M&A targets since 2017, with an average 58% premium paid on the deals.

Biotech is naturally volatile because a companys fortunes can pivot on the results of a single drug trial. IBTs managers attempt to reduce the impact of binary events that could send share prices up or down. What this means in practice is that they will reduce their exposure before the results of a critical trial, for example. While they might lose out on some of the last bit of outperformance from a stock by doing this, it also means they wont be so affected by a sharp share price fall if the trial ends unsuccessfully.

The International Biotechnology Trust is the only one of its peers to pay a yield. Following a dividend policy introduced in 2016, the dividend of 4% of NAV per annum is paid from capital effectively converting some of the underlying holdings capital growth into income each year making the trust a compelling option for income-seekers as well as growth investors. Given that this dividend is paid from capital, it is not contingent on receipt of income from underlying portfolio companies.

Delivering an annualised return of 15% a year over the last decade, biotechnology has outperformed the annualised 8.75% return from the MSCI World over the long term*. The sector offers diversification, innovation and compelling growth potential for those investors willing to take some risk over the long term.

*Source: SharePad and MSCI (annualised % change of the Nasdaq Biotechnology Index versus the MSCI World 28/02/2010- 28/02/2020)

Read more:
Harness the power of biotech for income and growth in uncertain times - What Investment

BEER-SHEVA, Israel, May 5, 2020 /PRNewswire/ -- The coronavirus, SARS-CoV-2, which is responsible for the current COVID-19 pandemic, is transmitted between people mainly via respiratory droplets, but it is known that the virus remains stable on various surfaces for days. One of the first indications for this came from the Diamond Princess cruise ship, where active virus particles were found even 17 days after the ship was evacuated. In light of the possibility that the virus can spread through contaminated surfaces, it is important to be able to sterilize surfaces with high contamination potential, such as doorknobs, elevator buttons or handrails in public areas in general, and in hospitals and clinics in particular. However, current disinfectants are mainly based on chemicals such as poisonous sodium hypochlorite (bleach) or alcohol, both of which provide only a temporary measure until the next exposure to the virus.

Prof. Angel Porgador, from the Department of Microbiology, Immunology and Genetics at Ben-Gurion University (BGU) and the National Institute of Biotechnology in the Negev (NIBN), and Dr. Mark Schvartzman, the Department of Materials Engineering at BGU, are developing novel surface coatings that will have a long term effect, and contain nanoparticles of safe metal ions and polymers with anti-viral and anti-microbial activity.

Certain metals can be lethal, even in small quantities, for viruses and bacteria and are not poisonous to humans. In proof of concept experiments, in which also PhD students Yariv Greenshpan and Esti Toledo, and postdoc Guillaume Le Saux participated, the researchers assessed the effect of surfaces coated with nanoparticles of various metals on the infectivity of lentiviruses, which belong to the HIV family, in human cells. Findings show that surfaces coated with copper nanoparticles strongly block infection of the cells by the virus. These ongoing experiments show a huge potential for copper ions in preventing surface-mediated infection with SARS-CoV-2.

Based on these findings, the researchers are developing anti-viral coatings that can be painted or sprayed on surfaces. The coatings are based on polymers, which are the starting materials of plastics and paints, and contain nanoparticles of copper and other metals. The nanoparticles embedded in the polymer will enable controlled release of metal ions onto the coated surface. Studies show that these ions have a strong anti-viral effect, which can eradicate virus particles that adhere to the surface. Because the release of ions is extremely slow, the coating can be effective for a long period of time weeks and even months, and it will reduce the infectivity of the virus particles by more than 10-fold.

Josh Peleg, CEO, BGN Technologies, said, "The need to develop anti-viral coatings has greatly increased recently, with the SARS-CoV-2 outbreak, and this need will likely remain high even after the pandemic ends, due to increased awareness. In addition, the product will be efficient as a general anti-viral and anti-bacterial coating. It can be applicable for medical settings, as an anti-pathogenic substance in places with increased risk of contamination, such as hospitals, but also for home use, and in public spaces such as schools, airports, public transportation and cinemas. We see a widespread and multidisciplinary academic commitment for finding solutions to currently medical and financial challenges as well as to the challenge of returning to normalcy once the pandemic wanes."

The research activity of Prof. Porgador and Dr. Schvartzman is part of the coronavirus research task force, founded by Prof. Daniel Chamovitz, President of BGU. To support this activity, it was decided to divert research funds in order to find rapid solutions for various challenges associated with the coronavirus pandemic. This invention received the support of the Israel Innovation Authority, in response to a call for proposals for coping with the coronavirus. The project is one of 27 proposals submitted to the Israel Innovation Authority by BGN Technologies, the technology transfer company of BGU, based on innovative and diverse inventions of researchers at BGU and the National Institute for Biotechnology in the Negev (NIBN) for the prevention, diagnosis and treatment of COVID-19.

Prof. Angel Porgador said, "The current coronavirus is transmitted not only through droplet spray but also via various surfaces that can convey the virus from one person to another. Furthermore, research shows that the virus remains viable on various surfaces for extended periods of time, of days and even longer. Therefore, there is a clear need for durable anti-viral coatings that can be sprayed or painted on surfaces, just like paint or varnish, and that will prevent viral transmission. These surfaces can include handles, buttons, railways or any other public surface that poses increased danger, in particular in places with a high concentration of potential carriers, such as hospitals or clinics. It is important to remember that we are developing coatings that will be effective not only against the coronavirus but also against other viruses, as indicated in our proof of concept experiments, and also against bacteria, so they will be relevant for a wide range of applications."

Dr. Mark Schvartzman commented, "While current surface disinfection methods rely mostly on substances that are poisonous for people, such as bleach, or on substances that evaporate readily being based on alcohol, the coating that we are developing is based on metals that are toxic for viruses or bacteria, but completely human friendly. It should be noted that until now using such metals for anti-viral applications has encountered significant challenges due to the nature of the metals, such as the tendency to oxidize and corrode. Nanoparticles provide a solution to these obstacles. Another advantage of nanoparticles is the large surface area to volume ratio, which results in an efficient anti-viral surface area using a relatively small amount of metal. Additionally, nanoparticles of anti-viral metal can be easily embedded in a polymer that can coat the relevant surfaces for extended periods of time."

About BGN Technologies

BGN Technologies is the technology company of Ben-Gurion University, Israel. The company brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchers and students. To date, BGN Technologies has established over 100 startup companies in the fields of biotech, hi-tech, and cleantech as well as initiating leading technology hubs, incubators, and accelerators. Over the past decade, it has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, IBM, PayPal, Cincinnati Children's Medical Center, Merck, Sigma and Bayer, securing value and growth for Ben-Gurion University as well as for the Negev region. For more information, visit the BGN Technologies website.

About NIBN

The National Institute for Biotechnology in the Negev Ltd. (NIBN), a unique research institute located within Ben-Gurion University of the Negev (BGU), is the first self-organized, independent research entity established under the auspices of a university in Israel.

The NIBN was established as a company in November 2009 through a trilateral agreement between the Israeli Government, Mr. Edgar de Picciotto, and Ben-Gurion University.

The mission of the NIBN is to conduct multi-disciplinary applied research guided by a clear biotechnology vision, to bridge the gap between basic and applied innovative research, and facilitate the commercialization of novel ideas and technologies developed by NIBN researchers.

Research at the NIBN is focused in several key areas: cancer, infectious diseases, autoimmune and metabolic diseases, human genetic disorders, neurodegenerative diseases, and applied biotechnology, including AgBio. The decision to focus on these topics combines existing strengths and resources unique to the NIBN and BGU. For more information, visit the NIBN website

Media Contact:

Tsipi HaitovskyGlobal Media LiaisonBGN TechnologiesTel: +972-52-598-9892E-mail: tsipihai5@gmail.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/scientists-at-ben-gurion-university-of-the-negev-develop-anti-coronavirus-surface-coating-based-on-nanomaterials-301052662.html

SOURCE BGN Technologies

Read the original:
Scientists at Ben-Gurion University of the Negev Develop Anti-Coronavirus Surface Coating Based on Nanomaterials - BioSpace

By Bassey Inyang

The Biotechnology Society of Nigeria (BSN) has announced that it has put in place measures to work with the federal government, through the Presidential Task Force (PTF) on Covid-19 and the National Centre for Disease Control (NCDC) towards containing the spread of the deadly virus in the country.

The society said that already, its members have established, A BSN Covid-19 Response Committee comprising highly competent Nigerian scientists to help the countrys efforts towards strategically containing the effect of this pandemic in the short and medium term.

The BSN made its offer to help in the fight against the pandemic known through a press release Monday.

BSN, in the statement signed by Prof. Benjamin Ewa Ubi and Mr. Yarama Ndirpaya, the National President and National Secretary respectively, as well as 10 other members indicated that it have already communicated with the PTF on Covid-19, the Ministry of Science and Technology, and the NCDC on the activities they have evolved to support the fight towards containing the spread of the Covid-19.

According to BSN, some of the measures include the mobilisation of its members and their intellectual resources at developing efficacious drugs for the successful treatment of patients that have contracted the Covid-19 as well as working towards the development of a vaccine that can be used in eliminating the virus.

The statement read in part: As partners in the fight against the Covid-19 pandemic, BSN has been developing a national response strategy to the crisis to advance different intervention areas where it can contribute in mitigating the resultant disruptions and shocks, as its contribution to safeguarding our country from the deadly novel coronavirus.

Drawing from insight and experiences of its several professionals in different fields of scientific endeavours, BSN is positioned to contribute to slowing down the transmission of the virus, and its management.

The society counts on her members with expertise in various fields (e.g. food and agricultural biotechnology, industrial biotechnology, environmental biotechnology, and medical biotechnology; and would harness their talents in supporting national efforts towards containing Covid-19 and mitigate its impact in our country.

Pointing out the roles the BSN can play effectively in containing the Covid-19 in the country, it said: Recognising that biotechnological tools and approaches are deployed to achieve robust outcomes in arresting the spread of the virus, and its attendant consequences in the short and medium term, BSN offers itself to play key roles in the following areas: Present qualified members to undertake coordinated and reinforced laboratory testing of Covid-19, starting from simple collection of qPCR analysis.

Galvanize BSN members to develop alternative testing techniques that will speed up testing of Covid-19 samples. Besides the use of RD testing for Covid-19, key members of BSN are in the process of developing alternative testing kits capable of detecting antigens from Covid-19 samples.

Those members are willing to support government efforts in synergy with NCDC and other relevant authorities.

Stressing that members of the BSN were working on possible medicinal remedy to the Covid-19, it said: Currently, various herbal therapies known to be efficacious against viral infections and symptoms of Covid-19 are being developed (and other herbal remedies have also been identified and proposed for further validation).

A specific case in point is that of one of our members who has successfully submitted an anti-Covid-19 mixture to the National Institute of Pharmaceutical Research and Development (NIPRD) for further evaluation following efficacy study of the mixture on different viruses of the respiratory tract and other organisms.

Continuing the BSN said its members who are molecular biologists are willing to contribute their expertise towards curtailing the Covid-19 pandemic, and that a team from one of BSN affiliated laboratories in Benin is currently developing and evaluating cost effective PCR diagnostics to circumvent the shortage of functional qPCR machines in the country.

BSN further disclosed that among other measures, some of its members have begun researches in vaccine development using various biotechnology and molecular biology techniques to collaborate with all relevant bodies including the private sector towards fast-tracking the development and use of innovations to combat the pandemic.

It commended the federal government and its agencies for the efforts they have put so far in combating the Covid-19 pandemic, and curbing the spread of its devastating effect on the lives of Nigerians and the nations economy.

The members of the BSN also condoled with President Muhammadu Buhari and families of Nigerians who have lost their loved ones to the Covid-19 pandemic.

Go here to see the original:
BSN to Work with FG to Contain Covid-19 - THISDAY Newspapers

LOS ANGELES--(BUSINESS WIRE)-- Myst Therapeutics (Myst), a preclinical stage biotechnology company focused on developing selected TIL-based autologous T cell (PuriT) therapy products for cancer, announced the appointment of George Smith, PhD, MBA as Vice President of Business Operations. Dr. Smith, who brings to Myst over 20 years of successful drug development experience at both biotechnology and global pharmaceutical companies, was previously the founder and lead for the Cell and Gene Therapy Center and Senior Director Portfolio and Innovation at IQVIA. Prior to IQVIA, he led R&D programs at Pfizer for 14 years and built multiple successful start-ups.

"Dr. Smith's vast experience in drug development from conception to approval will be instrumental to advancing Mysts PuriT products through multi-center clinical trials and on to registration," said TJ Langer President and Chief Executive Officer of Myst Therapeutics. "We are very pleased to welcome him to the Myst management team."

At IQVIA, George founded and built the Cell and Gene Therapy Center, a group of cell and gene therapy (CAGT) experts focused on preclinical, clinical and commercial development of CAGT therapeutics. He also led due diligence programs. Prior to IQVIA, he led R&D programs, scientific groups and translational medicine for the Antiviral and Therapeutic Vaccine Therapeutic Areas at Pfizer. He has helped build multiple successful start-ups, including Althea Technologies and K2 Biopharma. George is currently on the advisory board for Visicell Medical. "The innovative PuriT approach shows tremendous potential for inducing significant and durable remissions," said Dr. Smith. "Myst has a promising product pipeline and a very experienced management team. I am thrilled to join them in developing this new cancer modality."

Dr. Smith received his Doctorate from the University of California, San Diego based on his work at the Salk Institute and his MBA from the Rady School of Business at UCSD. He is an author of over 10 peer-review publications and has been a speaker at over 50 conferences.

About the PuriT Platform

Clinical evidence has demonstrated that a patients' tumor infiltrating lymphocytes (TIL) recognize tumor specific molecules, traffic to the tumor, respond to tumor antigen, and selectively eradicate tumors. Clinical studies using these cells have shown durable objective clinical responses in patients with advanced metastatic disease, including refractory melanoma, breast, cervical, and colorectal cancer. Mysts PuriT platform builds on these successes by enriching and rejuvenating TIL to further improve responses. These encouraging results highlight PuriT as an emerging modality capable of providing personalized therapy options for patients spanning a broad spectrum of diseases.

About Myst Therapeutics

Myst Therapeutics Inc. is a privately held, pre-clinical stage biotechnology company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patients own immune system to treat solid tumors. Myst is developing technologies to enable, scale and improve adoptive cell therapies with a focus on improving clinically effective neoantigen enriched T cell therapies for solid tumors. Myst has combined methods of identifying neoantigen reactive T cells from tumor infiltrating lymphocytes (TIL) with Mysts proprietary technologies and expertise in the development and manufacturing of cell therapies. We believe this combination will enable Myst to rapidly advance and commercialize highly promising and innovative therapies, addressing a wide range of advanced solid tumors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005109/en/

See the original post here:
Myst Therapeutics Appoints George Smith as Vice President of Business Operations - BioSpace

This report focuses on Global Food Biotechnology Market status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Food Biotechnology Market development in the United States, Europe, and China.

In 2019, the global Food Biotechnology Market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2025-2025.

The report also summarizes the various types of Food Biotechnology Market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of the Food Biotechnology Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts

Get Sample: https://www.lexisbusinessinsights.com/request-sample-129360

Top Key players: ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies Ltd, Dow AgroSciences LLC, DuPont Pioneer, Evogene Ltd, Hy-Line International, KWS Group, Monsanto, Origin Agritech Limited, and Syngenta AG

Food Biotechnology Market: Regional Segment Analysis.

This report provides pin-point analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed based on how the Food Biotechnology Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Food Biotechnology Market?

What are the key market trends impacting the growth of the Global Food Biotechnology Market?

What are the challenges to market growth?

Who are the key vendors in the Global Food Biotechnology Market?

What are the market opportunities and threats faced by the vendors in the Global Food Biotechnology Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Food Biotechnology Market;

3.) The North American Food Biotechnology Market;

4.) The European Food Biotechnology Market;

5.) Market entry and investment feasibility;

6.) The reports conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Food Biotechnology Market report will enlist all sections and research for every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining the market growth

It provides a six-year forecast assessed based on how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2025-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Global Food Biotechnology Market Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-129360

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight a huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far-reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from a number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

APAC: +91 98677 99788

[emailprotected]

http://www.lexisbusinessinsights.com

Read more here:
Global Food Biotechnology Market Research With Size, Share, Trends, Top Manufacturers, Regional Analysis, Business Growth, Applications, Emerging...